| 4197 pathological cardiac hypertrophy may slow or prevent the progress of hypertension to heart failure. Wu-Zhu-Yu used for antihypertensive therapy. 2 Rutaecarpine was shown to cause vasorelaxing in a concentration-dependent manner in rat aortic rings, inhibit anaphylaxis-induced vasoconstriction in guinea-pigs, and diminish blood pressure in anaesthetized rats. 3, 4 Furthermore, rutaecarpine inhibits an increase in systolic blood pressure in phenol-induced hypertensive rats and spontaneously hypertensive rats. 5, 6 In addition, our previous studies have demonstrated that rutaecarpine reduces systolic blood pressure in renovascular hypertensive rats. 7, 8 Taken together, these data suggest that rutaecarpine could be a potent antihypertensive agent.
Recently, rutaecarpine was shown to alleviate hypertensive cardiac hypertrophy in the rats subjected to abdominal artery constriction (AAC). 9 High blood pressure contributes to the development of cardiac hypertrophy. A variety of studies have stated that rutaecarpine reduces blood pressure by increasing the synthesis and release of calcitonin gene-related peptide (CGRP) and reducing the levels of angiotensin II (Ang II) as well as prolylcarboxypeptidase, a degrading enzyme of Ang II, in mesenteric artery of renohypertensive rats. 8, 10 These findings suggest that the depressor effect plays a key role in the beneficial action of rutaecarpine against hypertensive cardiac hypertrophy. Besides its depressor effect, it still needs to further elucidate about how rutaecarpine inhibits hypertensive cardiac hypertrophy. Our previous research indicated that NADPH oxidase 4 (Nox4) promotes Ang II-induced cardiac hypertrophy via the pathway of reactive oxygen species (ROS)-a disintegrin and metalloproteinase-17 (ADAM17) in cultured primary cardiomyocytes.
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Therefore, this study aimed to determine whether the Nox4-ROS-ADAM17 pathway is involved in the protective role of rutaecarpine in hypertensive cardiac hypertrophy in the rats subjected to AAC.
| MATERIAL S AND ME THODS

| Reagents
Rutaecarpine (84-26-4) was purchased from a commercial ser- 
| Animals
| Animal model of AAC-induced cardiac hypertrophy
Abdominal artery constriction was carried out to induce pathological cardiac hypertrophy through pressure overload, as previously described. 12, 13 In brief, the following procedures were described:
rats were anaesthetized with sodium pentobarbital through intraperitoneal injection before the surgery until toe pinch reflex dis- 
| Measurement of blood pressure
Systolic blood pressure (SBP) was measured in conscious state before the treatment with rutaecarpine, at the 2nd week and the 4th week after the treatment using tail-cuff method. 
| Echocardiographic evaluation
Transthoracic echocardiography was conducted using a Vevo 
| Haemodynamic measurement
Haemodynamic measurement was implemented in the rats as previously described. 12 After the rats were anaesthetized with sodium pentobarbital (ip, 45 mg/kg), a 24-gauge polyethylene catheter filled with heparin was introduced into the right carotid artery of rats, and systolic arterial blood pressure (SABP), diastolic arterial blood pressure (DABP) were measured using a BL-420S system (Chengdu Tai-meng Technology Co., Ltd, Sichuan, China). Next, the 24-gauge polyethylene catheter was further introduced into the left ventricle of rats. Finally, the BL-420S system was used to measure the maximal rate of left ventricular pressure increase (dp/dtmax) and decrease (dp/dtmin), and heart rate.
| Histological analysis
The hearts were arrested in diastole using potassium chloride cross-sectional area was measured in 10 randomly chosen nonrepeating fields in cross-sections stained with H&E using Image-pro plus 6.0 according to the method described previously. 16 Finally, interstitial fibrosis was quantified as the percentage of fibrotic area over the total myocardial area in five randomly chosen nonrepeating visual fields (excluding the fields that contained a coronary artery) of sections stained with Masson's trichrome reagent using Image-pro plus 6.0.
| Immunohistochemistry
Immunohistochemistry was used to detect the protein levels of col I, col III and TNF-α in the left ventricle as described previously. 
| Western blotting
Western blotting was executed according to the standard procedures previously described.
11,19
| Cell culture and drug treatment
Primary ventricular cardiomyocytes were isolated from 1-to 3-dayold Sprague-Dawley rats as described before. 
| Cell surface area
After fixed with 4% paraform, primary cardiomyocytes were permeabilized using 0.5% Triton X-100 and then incubated with TRITC-labeled phalloidin for 30 minutes at room temperature. Next, the cell surface area was automatically analysed in 40 nonrepeated fields of the cardiomyocytes using a Cellomics/High Content Screening (Thermo Scientific, Shanghai, China) as previously described. the cells were used to detect DHE fluorescence intensity using a Cellomics/High Content Screening (Thermo Scientific).
| Enzyme-linked immunosorbent assay
After cardiomyocytes were stimulated with Ang II for 24 hours, the conditioned DMEM was collected to detect the mature TNF-α released from myocardial cells. These samples were used to detect the TNF-α level by a TNF-α enzyme-linked immunosorbent assay kit (CSB-E11987r; Cusabio Biotech., Co. Ltd., Wuhan, China) according to the manufacturer's instructions.
| Statistical analysis
Data are expressed as mean ± SD. Statistical analysis was performed using one-way or two-way ANOVA followed by Bonferroni's post hoc test among at least three groups, and P < 0.05 was considered to have statistical significance.
| RE SULTS
| Effect of rutaecarpine on blood pressure in the rats subjected to AAC
For evaluating the effect of rutaecarpine on blood pressure, we compared SBP, SABP, and DABP obtained from the four groups.
As shown in LVIDs, LV internal diameter during systole; SABP, Systolic artery blood pressure; DABP, Diastolic artery blood pressure; dp/dtmax, the maximal rate of left ventricular pressure increase; dp/dtmin, the maximal rate of left ventricular pressure decrease. Data are mean ± SD. One-way ANOVA followed by post hoc test was carried out for the statistical tests. n = 10. # P < 0.05 vs Sham group.
*P < 0.05 vs AAC group. (Tables 1 and 2 ). Likewise, the AAC-induced hypertensive rats treated with low or high dosage of rutaecarpine exhibited increases in dp/dtmax and dp/dtmin, but no significant change in heart rate compared with the AAC group. Accordingly, rutaecarpine decreased blood pressure in AAC-induced hypertensive rats, consistently with its depressor effect reported by previous studies. (Table 2) .
Concurrently, the mRNA levels of hypertrophic genes, such as ANP and BNP, were significantly higher in the AAC group than those of the Sham group ( Figure 1D ). These evidences suggest that hypertensive cardiac hypertrophy is induced through AAC induction for 4 weeks. In contrast to the results observed in the AAC rats, treatment with low or high dosages of rutaecarpine remarkably attenuated hypertensive cardiac hypertrophy, as indicated by a decrease in the HW/BW, the LVW/BW, the myocyte cross-sectional area, the LVAWd, the LVAWs, the LVPWd, the LVPWs and the mRNA levels of hypertrophic genes, compared with those of the AAC group ( Figure 1 and Table 2 ). Moreover, low or high dosage of rutaecarpine significantly decreased the fibrotic area and the protein and mRNA levels of col I and col III in the left ventricle of AAC-induced hypertensive rats (Figure 2 ).
Taken together, rutaecarpine alleviated hypertensive cardiac hypertrophy.
F I G U R E 1 Rutaecarpine (Rut) inhibited hypertensive cardiac hypertrophy in the rats subjected to abdominal artery constriction (AAC).
A, HW/BW (n = 9-10 per group). B, LVW/BW (n = 9-10 per group). C, Cross-sections of the hearts from the rats subjected to AAC or sham operation were stained with haematoxylin & eosin to analyse myocyte cross-sectional area (n = 5 per group). D, Real-time PCR analyses of hypertrophic markers (ANP and BNP, n = 5 in each group). Rut (L) represents low dosage of rutaecarpine; Rut (H) represents high dosage of rutaecarpine; HW/BW represents the ratio between heart weight and body weight; LVW/BW represents the ratio between left ventricular weight and body weight. # P < 0.05 vs Sham group, *P < 0.05 vs SHR group. One-way ANOVA followed by Bonferroni's post hoc test was carried out for the statistical tests | 4201
| Rutaecarpine prevented Ang II-induced cardiac hypertrophy in primary cardiomyocytes
We subsequently observed the effect of rutaecarpine on pathological cardiac hypertrophy in vitro. In cardiomyocytes, pathological cardiac hypertrophy could be modeled through Ang II stimulation. 
| Rutaecarpine inhibited the Nox4-ROS-ADAM17 pathway in hypertrophic cardiomyocytes
To further delineate mechanisms underlying the inhibitory effect of rutaecarpine against hypertensive cardiac hypertrophy, we determined whether rutaecarpine suppressed the Nox4-ROS-ADAM17 pathway in hypertrophic cardiomyocytes. Firstly, we examined the hypothesis in primary cardiomyocytes. As can be seen from 
| Rutaecarpine blocked over-activation of the ERK1/2 pathway
We next determined whether rutaecarpine influenced the ERK1/2 pathway in hypertrophic cardiomyocytes because the ERK1/2 pathway has been proved to play a critical role in pathological cardiac hypertrophy. [26] [27] [28] The left ventricle of the AAC rats displayed increased activity of ERK1/2 compared with the Sham group, whereas low or F I G U R E 3 Rutaecarpine (Rut) alleviated angiotensin II (Ang II)-induced cardiac hypertrophy in primary cardiomyocytes. Primary cardiomyocytes were treated with 100 nmol/L angiotensin II for 24 h after pretreating with rutaecarpine (10 µmol/L) for 60 min. A, Cell surface area. B and C, The mRNA levels of hypertrophic genes ANP (B) and BNP (C). # P < 0.05 vs control group; *P < 0.05 vs Ang II group. The statistical tests were undertaken by one-way ANOVA followed by Bonferroni's post hoc test. n = 3 independent experiments high dosage of rutaecarpine remarkably decreased the phosphorylation level of ERK1/2 in the left ventricle of AAC-induced hypertensive rats ( Figure 6A) . Similarly, rutaecarpine down-regulated the ERK1/2 activity in cardiomyocytes stimulated with 100 nmol/L Ang II for 24 hours ( Figure 6B ). Therefore, rutaecarpine suppresses over-active ERK1/2 pathway in hypertrophic cardiomyocytes. 
| D ISCUSS I ON
In this research, we discovered that rutaecarpine alleviated hyper- 11 Taken together, the Nox4-ROS-ADAM17 pathway is required for hypertensive cardiac hypertrophy independent of blood pressure.
The data in AAC-induced hypertensive rats confirm the beneficial effect of rutaecarpine on hypertensive cardiac hypertrophy.
The finding that rutaecarpine significantly inhibits hypertensive cardiac hypertrophy in AAC-induced hypertensive rats supports its protective action against hypertensive cardiac hypertrophy. And this finding agrees with previous results that rutaecarpine attenuates isoprenaline-and AAC-induced pathological cardiac hypertrophy. 9, 41 In addition, we revealed that rutaecarpine inhibited the Nox4-ROS-ADAM17 pathway in the left ventricle of AAC-induced hypertensive rats and primary cardiomyocytes stimulated with Ang II. Accordingly, blocking the Nox4-ROS-ADAM17 pathway is related to the protective action of rutaecarpine against hypertensive cardiac hypertrophy.
ERK1/2 is a key member of the family of mitogen-activated protein kinase (MAPK). ERK1/2 activity within the heart is increased in aortic banding-induced hypertensive rats and spontaneously hypertensive rats, [42] [43] [44] in agreement with our findings that the heart exhibited elevated activity of ERK1/2 in AAC-induced hypertensive rats. In vitro studies have verified the positive effect of ERK1/2 on cardiac hypertrophy in cardiomyocytes treated with endothelin-1 or phenylephrine. 45, 46 Nevertheless, ERK1/2 deletion in the heart failed to suppress hypertensive F I G U R E 6 Rutaecarpine (Rut) blocked the over-activation of the extracellular signal-regulated kinase (ERK) 1/2 pathway in hypertrophic cardiomyocytes. A, ERK1/2 activity in the left ventricle of rats with abdominal artery constriction (AAC, n = 4 per group). Rut (L) represents low dosage of rutaecarpine; Rut (H) represents high dosage of rutaecarpine; # P < 0.05 vs Sham group, *P < 0.05 vs SHR group. B, ERK1/2 activity in primary cardiomyocytes treated with 100 nmol/L angiotensin II (Ang II) for 24 h (n = 3 independent experiments). After being pretreated with Rut (10 µmol/L) for 60 min, cardiomyocytes were then stimulated with 100 nmol/L Ang II for 24 h. # P < 0.05 vs Control group; *P < 0.05 vs Ang II group. The statistical analyses were executed using one-way ANOVA followed by Bonferroni's post hoc test cardiac hypertrophy after 14 days of Ang II or phenylephrine infusion in mice. 47 The possible explanation for this inconsistency might be that Ang II or phenylephrine infusion induces hypertensive cardiac hypertrophy through other signaling pathways such as p38 MAPK and JNK1/2 in mice with ERK1/2 deletion in the heart. However, ERK1/2 activation, induced by overexpression of MAPK1 within the heart, advances concentric cardiac hypertrophy. 26, 47 Hence, ERK1/2 plays an important role in hypertensive cardiac hypertrophy. In the current study, we discovered that rutaecarpine markedly reduced ERK1/2 activation in the left ventricle of AAC rats and primary cardiomyocytes stimulated with Ang II. Overall, the inhibition of ERK1/2 pathway is associated the protective action of rutaecarpine against hypertensive cardiac hypertrophy.
In conclusion, we revealed that rutaecarpine attenuates hypertensive cardiac hypertrophy in AAC-induced hypertensive rats;
and inhibiting the Nox4-ROS-ADAM17 pathway and over-activa- 
| DATA AVAIL AB ILIT Y
All data used to support the findings of this study are available from the corresponding authors upon request.
ACK N OWLED G EM ENTS
The authors thank Ms. Menzhen Zhang for her technical assistance General Hospital (grant number YQ2015-008).
CO N FLI C T S O F I NTE R E S T
The authors have no conflict of interest to disclose.
O RCI D
Si-yu Zeng https://orcid.org/0000-0003-1185-2658
